智康弘义第二款全球首创ADC BC2027获批美国临床-动脉橙

智康弘义第二款全球首创ADC BC2027获批美国临床

2024-04-09 BioSpace 等3家媒体报道 FDA动态





BioCity Biopharma宣布，FDA批准了其针对BC2027的第一阶段研究的IND申请，BC2027是该公司第二个针对癌细胞中发现的蛋白聚糖磷脂酰肌醇蛋白聚糖3（GPC3）的ADC。GPC3在肝癌，肺癌和食道癌中上调，使其成为合理的治疗靶点。BC2027以高亲和力与GPC3结合，有效内化到癌细胞中，并释放其抗癌有效载荷，在临床前研究中表现出强大的抗癌活性，抑制率超过90%。这标志着生物城在开发新型癌症治疗方法方面取得了重要的里程碑。（摘要由动脉网AI生成）

关联公司

 智康弘义

2024-04-09 BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

BioSpace
2024-04-09 BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

CISION
2024-04-10 BioCity Announces FDA Clearance of the Investigational New Drug Application for its First-In-Class Antibody Drug Conjugate Targeting Glypican 3

PHARMA FOCUS ASIA